创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

龙健灵, 徐蕙, 曾梦, 杨磊, 郑松柏. 非酒精性脂肪性肝炎诊断研究进展[J]. 药学进展, 2020, 44(3): 201-207.
引用本文: 龙健灵, 徐蕙, 曾梦, 杨磊, 郑松柏. 非酒精性脂肪性肝炎诊断研究进展[J]. 药学进展, 2020, 44(3): 201-207.
LONG Jianling, XU Hui, ZENG Meng, YANG Lei, ZHENG Songbai. Research Progress in Diagnosis of Non-alcoholic Steatohepatitis[J]. Progress in Pharmaceutical Sciences, 2020, 44(3): 201-207.
Citation: LONG Jianling, XU Hui, ZENG Meng, YANG Lei, ZHENG Songbai. Research Progress in Diagnosis of Non-alcoholic Steatohepatitis[J]. Progress in Pharmaceutical Sciences, 2020, 44(3): 201-207.

非酒精性脂肪性肝炎诊断研究进展

Research Progress in Diagnosis of Non-alcoholic Steatohepatitis

  • 摘要: 非酒精性脂肪性肝病是一种慢性非传染性疾病。近年来其患病率和发病率不断增高,发病年龄也出现低年龄化趋势,该疾病已取代慢性乙型肝炎成为第一大慢性肝脏疾病。重点综述非酒精性脂肪性肝病中的非酒精性脂肪性肝炎的诊断研究进展,介绍非酒精性脂肪性肝炎的临床病史、病理学诊断、非侵入方法诊断,为临床诊断提供参考。

     

    Abstract: Non-alcoholic fatty liver disease (NAFLD) is a chronic, non-communicable disease. In recent years, the prevalence and incidence of NAFLD have been increasing, while the age of onset has been decreasing. It has replaced chronic hepatitis B as the first chronic liver disease. This article reviews the research progress in the diagnosis of non-alcoholic steatohepatitis (NASH), and introduces the clinical history, pathological diagnosis and non-invasive diagnosis of NASH, in order to provide reference for clinical diagnosis of the disease.

     

/

返回文章
返回